Fig. 2
From: Local delivery of accutox® synergises with immune-checkpoint inhibitors at disrupting tumor growth
AccuTOX® synergises with ICI at impairing tumor growth. A Schematic diagram showing the approach used for the in vivo studies using three cancer models. B Assessment of EL4 tumor volume overtime when combined with anti-PD-1, anti-CTLA4 or anti-CD47. The color code is as follows: control (black), AccuTOX® (green), AccuTOX® + anti-PD-1 (orange), AccuTOX® + anti-CTLA-4 (red), AccuTOX® + anti-CD47 (yellow). C Kaplan–Meier survival curve for the experiment in panel B. D Assessment of E0771 tumor volume overtime when combined with anti-PD-1, anti-CTLA4 or anti-CD47. The color code is as follows: control (black), anti-PD-1 (green), anti-CLTA-4 (purple), anti-CD47 (gray), AccuTOX® (blue), AccuTOX® + anti-PD-1 (orange), AccuTOX® + anti-CTLA-4 (red) and AccuTOX® + anti-CD47 (yellow). E Kaplan–Meier survival curve for the experiment in panel D. F Assessment of B16 tumor volume overtime when combined with anti-PD-1, anti-CTLA4 or anti-CD47. The color code is as follows: control (black), anti-PD-1 (green), anti-CLTA-4 (purple), anti-CD47 (blue), AccuTOX® (gray), AccuTOX® + anti-PD-1 (orange), AccuTOX® + anti-CTLA-4 (red) and AccuTOX® + anti-CD47 (yellow). G Kaplan–Meier survival curve for the experiment in panel F. H) Assessment of B16 tumor volume overtime in response to Accum® (green) or AccuTOX® (red) in combination with anti-PD-1. I Kaplan–Meier survival curve for the experiment in panel H. For all in vivo panels shown in panels B-G, n = 5/group with *P < 0.05, **P < 0.01, and ***P < 0.001. For the in vivo experiment shown in panels H-I, n = 10/group. The in vivo experiments were repeated twice